Navigation Links
Syndax Pharmaceuticals' Entinostat in Combination Shows Activity in Breast Cancer
Date:12/10/2010

to see results in the first half of next year."

The University of Maryland study looked at the ability of entinostat to restore responsiveness of letrozole resistant MCF-7Ca xenografts to aromatase inhibitors. Entinostat was able to increase estrogen receptor expression and aromatase activity in the letrozole resistant tumors. The results suggest that entinostat may modulate Her-2 signaling and reverse the acquired resistance to letrozole caused by up-regulation of estrogen independent growth factor signaling pathways.

"While aromatase inhibitors have significantly improved the outcomes of hormone responsive post-menopausal breast cancer, not all tumors respond and many eventually acquire resistance," said Gauri J. Sabnis, Ph.D., assistant professor of pharmacology and experimental therapeutics at the University of Maryland School of Medicine. "These animal models have been confirmed in the clinic giving us hope that entinostat, if approved, will provide these women with a new treatment option to help overcome the resistance that many of them experience while on aromatase inhibitors."

Triple negative breast cancer (TNBC) is a sub-group of breast cancer that is normally unresponsive to hormone therapy as well as many forms of chemotherapy. Researchers from Johns Hopkins University School of Medicine reasoned that combining epigenetic therapy, entinostat, with differentiation therapy, retinoic acid receptor beta 2 agonist (ATRA) will provide an effective combination of drugs against TNBC. Low-doses of chemotherapy also were added to the combination. The results showed that entinostat plus ATRA and doxorubicin has the potential to be an effective treatment against TNBC.

"These findings provide encouraging new information for a non-toxic and novel combination of drugs with entinostat that could be effective in the treatment of triple negative breast cancer -- a condition desperately in need of new treatments," said Sara Sukumar, Ph.D., p
'/>"/>

SOURCE Syndax Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Syndax Pharmaceuticals Entinostat Plus Erlotinib Improves Survival in Select NSCLC Patients
2. Syndax Pharmaceuticals Announces Issuance of UK Patent for Entinostat
3. Syndax Pharmaceuticals to Present at Sachs Biotech in Europe Investor Forum
4. Syndax Pharmaceuticals Entinostat Shows Clinical Promise in Patients with Advanced Hormone Refractory Breast Cancer
5. Arena Pharmaceuticals Initiates Phase 1 Clinical Trial of APD811 for Pulmonary Arterial Hypertension
6. Access Pharmaceuticals Reports Significant Third Party Payer Reimbursement Progress for MuGard
7. Lotus Pharmaceuticals Announces Update on Land in Inner Mongolia
8. Reportlinker Adds Global Generic Pharmaceuticals Industry Report
9. Cipher Pharmaceuticals Using MedAvante Centralized Ratings in Phase 3 Study
10. Data from Phase 2 Study of Alder Biopharmaceuticals Anti-IL-6 Antibody Therapeutic, ALD518, Demonstrate Reversal of Anemia in Patients with Advanced Non-Small Cell Lung Cancer
11. Topaz Pharmaceuticals Announces Completion of Pivotal Phase 3 Trials of Ivermectin Topical Cream
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... , Jan. 15, 2014  According to Millennium Research ... market intelligence, the United States ... device markets will expand moderately through 2022, with ... In particular, increasing interest in drug-eluting beads (DEBs) ...
(Date:1/15/2014)... YORK , Jan. 15, 2014 ... report is available in its catalogue: ... India Drug Forecast and Market Analysis to ... PharmaPoint: Atopic Dermatitis - India Drug ...
(Date:1/15/2014)... NEW YORK , Jan. 15, 2014 ... research report is available in its catalogue: ... Technologies for Advanced Drug Delivery Systems -- ... http://www.reportlinker.com/p01940411/Global-Markets-and-Technologies-for-Advanced-Drug-Delivery-Systems----Focus-on-End-Users.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_Delivery_Technology STUDY OBJECTIVES ...
Breaking Medicine Technology:US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 2US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 2PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 4PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 2Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 4Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 6Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 7Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 8Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 9Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 10Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 11Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 12Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 13Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 14Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 15Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 16Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 17Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 18
... 1, 2010 Elsevier, the leading,publisher of scientific, technical and ... the newly formed Global Sales &,Customer Marketing group in the Science ... Government, Books and Corporate,Markets, effective 1 July. , ... O,Malley,s appointment ...
... June 30 Dendreon Corporation (Nasdaq: ... Medicaid Services (CMS) today initiated a National Coverage Analysis (NCA) ... treatment of asymptomatic or minimally symptomatic metastatic, castrate-resistant (hormone-refractory) ... new therapeutic class known as autologous cellular immunotherapies. , ...
Cached Medicine Technology:Elsevier Appoints Martin O'Malley as Managing Director of New Global Sales Group in Science & Technology Division 2Elsevier Appoints Martin O'Malley as Managing Director of New Global Sales Group in Science & Technology Division 3Elsevier Appoints Martin O'Malley as Managing Director of New Global Sales Group in Science & Technology Division 4Dendreon Statement on CMS National Coverage Analysis 2Dendreon Statement on CMS National Coverage Analysis 3Dendreon Statement on CMS National Coverage Analysis 4
(Date:7/9/2014)... acute episodes of low back pain are not linked ... wind direction and precipitation. Findings published in Arthritis ... College of Rheumatology (ACR), indicate that the risk of ... or wind gusts, but was not clinically significant. ... everyone experiences low back pain at some point in ...
(Date:7/9/2014)... types of cancer sends the protein factories in our ... uncontrolled growth, new research suggests. , Scientists at The ... responsible for ratcheting up activity of the endoplasmic reticulum ... blocks cancer cells need to keep growing. , A ... the flow of messages to the endoplasmic reticulum telling ...
(Date:7/9/2014)... found that fecal transplantation is effective and safe for ... is the result of a study led by Colleen ... Gastrointestinal Medicine at The Women,s Medicine Collaborative. The study ... of print in the American Journal of Gastroenterology ... diff , has increased to epidemic proportions over the ...
(Date:7/9/2014)... DALLAS July 9, 2014 There has been ... at UT Southwestern Medical Center using MyChart, the online, ... radiology results, communicate with their healthcare providers, schedule appointments, ... number of patients actively using MyChart each ... each year increased more than 10-fold, according to a ...
(Date:7/9/2014)... of Allergy and Infectious Diseases (NIAID), part of ... early-stage clinical trial of CRS3123, an investigational oral ... ( C. difficile ) infection. CRS3123 (previously known ... C. difficile growth while sparing normal intestinal bacteria. ... to 30 healthy men and women ages 18 ...
Breaking Medicine News(10 mins):Health News:Low back pain? Don't blame the weather 2Health News:Signal may send cancer's cellular factories into overdrive 2Health News:Women's Medicine Collaborative examines safety of fecal transplant to treat C. difficile 2Health News:MyChart use skyrocketing among cancer patients, UT Southwestern study finds 2Health News:MyChart use skyrocketing among cancer patients, UT Southwestern study finds 3Health News:NIH launches Phase I clinical trial of novel drug to treat Clostridium difficile infection 2
... WeissComm Group today announced the acquisition of ... company founded by Bob Pearson , who will ... that it has signed a strategic alliance with Rule ... and training. Pearson will continue to operate and grow this ...
... May 27 eCardio Diagnostics ( www.ecardio.com ... is a finalist for the Ernst & Young Entrepreneur ... Houston & Gulf Coast Area Program. According to ... who demonstrate extraordinary success in the areas of innovation, ...
... 27 Autism is a neurobiological condition which is ... some health insurance companies, especially HMOs, fail to cover ... Wellspring, a leader in autism treatment, is excited to ... with their CA health insurance plan to cover autism ...
... term follow-up indicates modest efficacy in primary and ... Ceregene, Inc. today reported additional clinical data ... CERE-120 in 58 patients with advanced Parkinson,s disease. ... the neurotrophic factor, neurturin, to Parkinson,s disease patients ...
... 27 The incidence of cardiovascular disease is ... smoking and other cardiac ailments. Each year cardiovascular ... 48 per cent of all mortalities in Europe.(Logo: ... cardiac rhythm management (CRM) market offers significant growth ...
... laser therapy, is a new treatment that provides proven pain relief and ... offered by The Laser Pain Management Center in Western Massachusetts. , ... ... adverse affect on every aspect of daily life. Low level laser therapy ...
Cached Medicine News:Health News:WeissComm Group Acquires Common Sense Media Group, Appoints Founder Bob Pearson Chief Technology and Media Officer to Help Clients Evaluate and Optimize Social Media 2Health News:WeissComm Group Acquires Common Sense Media Group, Appoints Founder Bob Pearson Chief Technology and Media Officer to Help Clients Evaluate and Optimize Social Media 3Health News:WeissComm Group Acquires Common Sense Media Group, Appoints Founder Bob Pearson Chief Technology and Media Officer to Help Clients Evaluate and Optimize Social Media 4Health News:eCardio Chief Executive Officer Larry Lawson Named Ernst & Young Entrepreneur Of The Year(R) 2009 Award Finalist in the Houston & Gulf Coast Area Program 2Health News:Wellspring Coordinates With CA Health Insurance Plans to Pay for Autism Treatments 2Health News:Ceregene Presents Additional Clinical Data from Phase 2 Trial of CERE-120 for Parkinson's Disease 2Health News:Ceregene Presents Additional Clinical Data from Phase 2 Trial of CERE-120 for Parkinson's Disease 3Health News:Ceregene Presents Additional Clinical Data from Phase 2 Trial of CERE-120 for Parkinson's Disease 4Health News:Ceregene Presents Additional Clinical Data from Phase 2 Trial of CERE-120 for Parkinson's Disease 5Health News:Advanced Technologies Pump Growth Into European Cardiac Rhythm Management Market, Affirms Frost & Sullivan 2Health News:Advanced Technologies Pump Growth Into European Cardiac Rhythm Management Market, Affirms Frost & Sullivan 3Health News:Advanced Technologies Pump Growth Into European Cardiac Rhythm Management Market, Affirms Frost & Sullivan 4Health News:New Non-Surgical Laser Treatment Helps Patients Live Pain Free 2Health News:New Non-Surgical Laser Treatment Helps Patients Live Pain Free 3
... generators are meeting the clinical needs ... and anesthesiologists. And, they are of ... from Medtronic.,Effective pacing with the adjustment ... for quick battery changes. Both ...
... CardioVad is a unique left ventricular assist device ... It is being used in a small group ... as part of an FDA-approved Feasibility Study. The ... the external power source for minutes or hours. ...
... Inc. has introduced the world's first minimally-invasive ... 10626 Epicardial Lead Implant Tool, which has ... States, will expand the options available to ... 5071 lead on the heart during pacemaker ...
The Schiller treadmill ergometer is designed for stress tests, sports medicine and cardiology. It is equipped and tested with the latest safety system and has been manufactured under the stringent qu...
Medicine Products: